FDA confirms Eli Lilly resolves Mounjaro and Zepbound shortage, investing in manufacturing capacity.

Eli Lilly's weight-loss and diabetes medications, Mounjaro and Zepbound, are no longer in shortage, according to the FDA. The company has resolved supply issues by investing billions in manufacturing capacity. While national demand can now be met, localized supply disruptions may still occur. The FDA warns that compounded versions of these drugs, which emerged during the shortage, are not FDA-approved and may lack rigorous safety testing.

October 02, 2024
38 Articles

Further Reading